Equibles does not estimate personal net worth.
Get an email with a short summary when Nautilus Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get NAUT alertsAnna Mowry is recorded as CFO at Nautilus Biotechnology, Inc. (NAUT). The newest filing on record that lists Anna Mowry as CFO at Nautilus Biotechnology, Inc. (NAUT) is dated April 28, 2026. The proxy statement of Nautilus Biotechnology, Inc. reports total compensation of $712,426 for Anna Mowry in fiscal 2025, including a base salary of $440,000. Disclosed compensation is on record for 3 fiscal years. Anna Mowry has spoken on 22 earnings calls across 1 company, most recently for Nautilus Biotechnology, Inc. on October 27, 2026. Nautilus Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nautilus Biotechnology, Inc. includes Sujal Patel (CEO and Board Member), Matt Murphy (General Counsel), Matthew Murphy (General Counsel) and 7 others.
“Our results this quarter reflect where we are as a company, in an early commercial phase with revenue coming from early access services and grant funding and the commercial launch of the Voyager platform still ahead of us.”
“Let me start with the commercial and customer picture and then I'll take you through the numbers, the resource shift, and our expectations for the coming quarters.”
“Turning to our financial update, we continue to demonstrate prudent management of both operating expenses and cash, and we remain on track or better against the full-year guidance we previously provided.”
“Turning to our financial results, we continued to demonstrate strong operating discipline in Q4 and throughout 2025. Total operating expenses were $15.4 million for the fourth quarter of 2025, a decrease of 23% from the prior year period, and $66.8 million for the fiscal year 2025, a decrease of 18% year-over-year.”
“For the third quarter of 2025, total operating expenses were $15.5 million, down from $19.1 million in the same quarter of 2024. This 19% year-over-year decrease reflects our continued focus on expense management, operating efficiency, and lower development costs overall.”
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Nautilus Biotechnology, Inc. (NAUT) | Chief Financial Officer | $440,000 | $712,426 |
| 2023 | Nautilus Biotechnology, Inc. (NAUT) | Chief Financial Officer and Treasurer | $386,000 | $781,519 |
| 2022 | Nautilus Biotechnology, Inc. (NAUT) | Chief Financial Officer and Treasurer | $364,000 | $1,347,175 |
